Aberrant alternative splicing pattern of ADAR2 downregulates adenosine-to-inosine editing in glioma

Li,Zhaohui; Tian,Yu; Tian,Nan; Zhao,Xingli; Du,Chao; Han,Liang; Zhang,Haishan

doi:10.3892/or.2015.3907

Aberrant alternative splicing pattern of ADAR2 downregulates adenosine-to-inosine editing in glioma

Authors:
- Zhaohui Li
- Yu Tian
- Nan Tian
- Xingli Zhao
- Chao Du
- Liang Han
- Haishan Zhang
View Affiliations

Affiliations: Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Cell Biology, College of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Surgery Institute, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: April 8, 2015 https://doi.org/10.3892/or.2015.3907
Pages: 2845-2852

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adenosine-to-inosine (A-to-I) RNA editing is the most common type of RNA editing in mammals, and is catalyzed by adenosine deaminases acting on RNA (ADARs). ADAR2 is the main enzyme responsible for A-to-I editing in humans, and A-to-I underediting at the glutamine (Q)/arginine (R) site of the glutamate receptor subunit B (GluR-B) is associated with the pathogenesis and invasiveness of glioma. The level of ADAR2 mRNA expression and the alternative splicing of the ADAR2 pre-mRNA both affect the catalytic activity of ADAR2. However, reports of ADAR2 mRNA expression in glioma are inconsistent. The mechanism regulating ADAR2 pre-mRNA splicing is also unknown. In this study, we explored the deregulation of A-to-I RNA editing in glioma. We confirmed the underediting at the Q/R site of GluR-B mRNA in the glioma cell lines U87, U251 and A172 compared with that in normal human astrocytes (NHAs) HA1800. However, we demonstrated with reverse transcription (RT-PCR) and quantitative PCR (qPCR) that the expression of ADAR2 mRNA was not significantly altered in the glioma cell lines. Three alternative splicing sites are utilized in the glioma cell lines and NHAs: the first, located between exons -1 and 1, causes the inclusion of exon 1a; the second causes the removal of exon 2, which encodes two double-stranded RNA-binding domains; and the third, located between exons 4 and 6, causes the inclusion of alternative exon 5a, introducing a 120-nucleotide coding Alu-repeat sequence in frame. However, the expression ratio of two types of transcripts (with and without exon 5a) was altered in the glioma cells. Transcripts with exon 5a, which generate an ADAR2 isoform with ~50% reduced activity, were predominantly expressed in the glioma cell lines, whereas transcripts without exon 5a were predominantly expressed in the NHAs. From these results, we conclude that this aberrant alternative splicing pattern of ADAR2 downregulates A-to-I editing in glioma.

View Figures

View References

1	Tang W, Fei Y and Page M: Biological significance of RNA editing in cells. Mol Biotechnol. 52:91–100. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jacobs MM, Fogg RL, Emeson RB and Stanwood GD: ADAR1 and ADAR2 expression and editing activity during forebrain development. Dev Neurosci. 31:223–237. 2009. View Article : Google Scholar : PubMed/NCBI
3	Goodman RA, Macbeth MR and Beal PA: ADAR proteins: structure and catalytic mechanism. Curr Top Microbiol Immunol. 353:1–33. 2012.
4	George CX, Gan Z, Liu Y and Samuel CE: Adenosine deaminases acting on RNA, RNA editing, and interferon action. J Interferon Cytokine Res. 31:99–117. 2011. View Article : Google Scholar :
5	Kubota-Sakashita M, Iwamoto K, Bundo M and Kato T: A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia. Mol Brain. 7:52014. View Article : Google Scholar : PubMed/NCBI
6	Slotkin W and Nishikura K: Adenosine-to-inosine RNA editing and human disease. Genome Med. 5:105–112. 2013. View Article : Google Scholar : PubMed/NCBI
7	Avesson L and Barry G: The emerging role of RNA and DNA editing in cancer. Biochim Biophys Acta. 1845:308–316. 2014.PubMed/NCBI
8	Galeano F, Tomaselli S, Locatelli F and Gallo A: A-to-I RNA editing: The ‘ADAR’ side of human cancer. Semin Cell Dev Biol. 23:244–250. 2012. View Article : Google Scholar
9	Dominissini D, Moshitch-Moshkovitz S, Amariglio N and Rechavi G: Adenosine-to-inosine RNA editing meets cancer. Carcinogenesis. 32:1569–1577. 2011. View Article : Google Scholar : PubMed/NCBI
10	Maas S, Patt S, Schrey M and Rich A: Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA. 98:14687–14692. 2001. View Article : Google Scholar : PubMed/NCBI
11	Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z, Constantini S, Barbash ZS, Adamsky K, Safran M, Hirschberg A, et al: Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 17:1586–1595. 2007. View Article : Google Scholar : PubMed/NCBI
12	Cenci C, Barzotti R, Galeano F, Corbelli S, Rota R, Massimi L, Di Rocco C, O’Connell MA and Gallo A: Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem. 283:7251–7260. 2008. View Article : Google Scholar : PubMed/NCBI
13	Tomaselli S, Galeano F, Massimi L, Di Rocco C, Lauriola L, Mastronuzzi A, Locatelli F and Gallo A: ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas. BMC Cancer. 13:255–260. 2013. View Article : Google Scholar : PubMed/NCBI
14	Gerber A, O’Connell MA and Keller W: Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. RNA. 3:453–463. 1997.PubMed/NCBI
15	Lai F, Chen CX, Carter KC and Nishikura K: Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. Mol Cell Biol. 17:2413–2424. 1997.PubMed/NCBI
16	Rueter SM, Dawson TR and Emeson RB: Regulation of alternative splicing by RNA editing. Nature. 399:75–80. 1999. View Article : Google Scholar : PubMed/NCBI
17	Slavov D and Gardiner K: Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing patterns. Gene. 299:83–94. 2002. View Article : Google Scholar : PubMed/NCBI
18	Kawahara Y, Ito K, Ito M, Tsuji S and Kwak S: Novel splice variants of human ADAR2 mRNA: skipping of the exon encoding the dsRNA-binding domains, and multiple C-terminal splice sites. Gene. 363:193–201. 2005. View Article : Google Scholar : PubMed/NCBI
19	Maas S and Gommans WM: Novel exon of mammalian ADAR2 extends open reading frame. PLoS One. 4:e42252009. View Article : Google Scholar : PubMed/NCBI
20	Agranat L, Sperling J and Sperling R: A novel tissue-specific alternatively spliced form of the A-to-I RNA editing enzyme ADAR2. RNA Biol. 7:253–262. 2010. View Article : Google Scholar : PubMed/NCBI
21	Galeano F, Rossetti C, Tomaselli S, Cifaldi L, Lezzerini M, Pezzullo M, Boldrini R, Massimi L, Di Rocco CM, Locatelli F, et al: ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene. 32:998–1009. 2013. View Article : Google Scholar :
22	Kim YJ and Kim HS: Alternative splicing and its impact as a cancer diagnostic marker. Genomics Inform. 10:74–80. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhang J and Manley JL: Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov. 3:1228–1237. 2013. View Article : Google Scholar : PubMed/NCBI
24	Oltean S and Bates DO: Hallmarks of alternative splicing in cancer. Oncogene. 33:5311–5318. 2014. View Article : Google Scholar
25	Sette C, Ladomery M and Ghigna C: Alternative splicing: role in cancer development and progression. Int J Cell Biol. 2013:4216062013.PubMed/NCBI
26	Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G and Ghigna C: Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol. 2013:9620382013. View Article : Google Scholar : PubMed/NCBI
27	Liu S and Cheng C: Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA. 4:547–566. 2013. View Article : Google Scholar : PubMed/NCBI